result expect begin
differenti market guidanc look
conserv catalyst path robust suggest
stock like move higher reiter overweight pt
deliv well expect deliv sale vs
mse beat preview see sale repres
y/i growth adjust stock de-stock underli procedur volum
healthi definit outperform peer us
q/q vs pend result estim
took bp share quarter result solid mark
import shift sentiment derisk outlook next year
underli market growth company-specif procedur volum healthi
manag strateg direct bear fruit two consecut
quarter improv perform share gain earli omnia see
detail descript omnia feedback posit discuss
repres underappreci catalyst partial pdn data
come nan
guidanc conserv guidanc rais vs
prior impli high end impli
pt momentum deceler guidanc prudent set
earli new manag tenur high end rang still repres
upsid vs rais beat rais
high end vs beat comfort high
end rang note momentum stabil vs impli
addit upsid note guidanc doesnt assum omnia benefit
there like limit contribut given approv receiv earlier
earli thought given underli procedur volum high teen
comfort us growth estim model
ww sale repres ww growth estim support
expect return us peer growth omnia drive
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
bp share captur earli feedback omnia encourag could
game chang strategi highlight omnia includ omnia
remain product hf best class data multi-mod
addit direct industri go elimin physician
fear around option refractori hf patient option better
program reduc burden commerci infrastructur deal
refractori patient ex us expect manag make greater push
toward implement chang european australian market
model growth
clinic catalyst manag present partial pdn data
full data set expect present
later like submit data fda expand claim
begin discuss payor back peer review
data public said expect physician interest pdn increas
post nan present commerci payor coverag
import broader traction point discuss deep diver
pdn note see uln manag uncertain market size warrant
rct fda demand still evalu option nsrbp continu
enrol
evid traction pt overweight thesi base
improv market compani growth driven commerci initi
improv growth ceo keith grossman recept new product
launch notabl omnia clinic data pdn updat
nsrpb trial serv key catalyst visibl expans rais
pt prior increas sale estim
street believ becom clear there path
sustain double-digit growth pt base sale
still repres meaning discount high growth smid-cap comp
group sale question market growth remain unansw
price target reflect multipl
base case sale high growth smid cap med-tech comp
bull sale
bull sale
materi share gain expans market growth near term
acceler innov new indic progress faster
timelin expect combin better expect share gain
drive sale acceler high teen lead substanti
re-rat multipl
base sale support dcf base analysi
base sale support dcf base analysi
inflect headwind omnia launch late
launch lead materi acceler share gain grow
mid-teen expans initi drive market growth enthusiasm
near data readout
bear sale
bear sale
growth slow competit headwind less differenti omnia
launch fail catalyz sale less differenti combin upstart
competit execut issu lead growth mid singl digit lead
multipl contract
believ new platform launch
late catalyz acceler share
gain
competit risk clinic
product perspect well understood
clinic data expand key
data pain diabet neuropathi non-
surgic back come
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
competit launch data on-going
risk achiev price
and/or omnia launch fail catalyz
upstart competitor could acquir
and/or obtain fund launch take
million except ep
revenu
sale
sale
sale
sale
sale
sale
dollar million except per share data
good sold
dollar million except per share data
rest world
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc
purchas invest
proce matur invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
